{
    "clinical_study": {
        "@rank": "48795", 
        "brief_summary": {
            "textblock": "To compare two lipid emulsions in the long-term parenteral alimentation of patients with\n      AIDS in relation to: Clinical effectiveness. Effect on immunologic function. Effect on HIV\n      load as measured by p24 antigen levels. Effect on relative HIV infectivity."
        }, 
        "brief_title": "Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT).\n\n          -  All drugs used for the standard treatment of opportunistic infections.\n\n          -  Other drugs used for the treatment of other AIDS conditions if they have been started\n             more than 3 months prior to study entry.\n\n        Patients must have:\n\n          -  Diagnosis of AIDS.\n\n          -  Weight loss of > 10 percent premorbid body weight.\n\n          -  Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma.\n\n          -  Require home total parenteral nutrition (TPN) for a period of approximately 3 months.\n\n          -  Life expectancy = or > 90 days.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Life expectancy < 90 days.\n\n          -  Biliary stasis.\n\n          -  History of drug abuse.\n\n        Patients with the following are excluded:\n\n          -  Life expectancy < 90 days.\n\n          -  Biliary stasis.\n\n          -  History of drug abuse.\n\n        Prior Medication:\n\n        Excluded within 3 months of study entry:\n\n          -  Immunomodulators.\n\n          -  Experimental antiviral DT. History of drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002029", 
            "org_study_id": "041A"
        }, 
        "intervention": [
            {
                "intervention_name": "Fat Emulsion 2%", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Fat Emulsion 20%", 
                "intervention_type": "Drug"
            }
        ], 
        "keyword": [
            "Weight Loss", 
            "Parenteral Nutrition, Total", 
            "AIDS-Related Opportunistic Infections", 
            "Liposyn", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "February 19, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33126"
                    }, 
                    "name": "Intracare Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Orange", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07018"
                    }, 
                    "name": "East Orange Veterans Administration Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "1556814", 
            "citation": "Singer P, Rubinstein A, Askanazi J, Calvelli T, Lazarus T, Kirvel\u00e4 O, Katz DP. Clinical and immunologic effects of lipid-based parenteral nutrition in AIDS. JPEN J Parenter Enteral Nutr. 1992 Mar-Apr;16(2):165-7."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002029"
        }, 
        "source": "Abbott", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2009"
    }, 
    "geocoordinates": {
        "East Orange Veterans Administration Med Ctr": "40.767 -74.205", 
        "Intracare Inc": "25.789 -80.226"
    }
}